Nuvalent, Inc. (NASDAQ:NUVL – Get Free Report) CFO Alexandra Balcom sold 11,430 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $98.69, for a total value of $1,128,026.70. Following the completion of the transaction, the chief financial officer directly owned 85,533 shares in the company, valued at approximately $8,441,251.77. This trade represents a 11.79% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Alexandra Balcom also recently made the following trade(s):
- On Wednesday, April 1st, Alexandra Balcom sold 11,430 shares of Nuvalent stock. The shares were sold at an average price of $105.21, for a total value of $1,202,550.30.
Nuvalent Stock Performance
Shares of NUVL opened at $94.02 on Friday. Nuvalent, Inc. has a 52-week low of $71.13 and a 52-week high of $113.01. The business’s 50 day moving average price is $102.71 and its two-hundred day moving average price is $103.20. The firm has a market cap of $7.43 billion, a PE ratio of -15.51 and a beta of 1.15.
Institutional Investors Weigh In On Nuvalent
Institutional investors have recently bought and sold shares of the stock. GAMMA Investing LLC grew its holdings in Nuvalent by 47.6% during the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock worth $34,000 after buying an additional 108 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Nuvalent by 141.3% during the first quarter. EverSource Wealth Advisors LLC now owns 333 shares of the company’s stock worth $34,000 after buying an additional 195 shares in the last quarter. Aster Capital Management DIFC Ltd bought a new stake in Nuvalent during the third quarter worth $38,000. NBC Securities Inc. bought a new stake in Nuvalent during the fourth quarter worth $125,000. Finally, KBC Group NV grew its holdings in Nuvalent by 24.1% during the fourth quarter. KBC Group NV now owns 1,527 shares of the company’s stock worth $154,000 after buying an additional 297 shares in the last quarter. Institutional investors own 97.26% of the company’s stock.
Analysts Set New Price Targets
Several equities research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and set a $155.00 price objective on shares of Nuvalent in a report on Tuesday, April 21st. Wells Fargo & Company assumed coverage on Nuvalent in a report on Monday, March 30th. They set an “overweight” rating and a $116.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvalent in a report on Tuesday, April 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Nuvalent in a report on Tuesday. Finally, Wedbush restated an “outperform” rating and set a $125.00 price objective on shares of Nuvalent in a report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $141.24.
View Our Latest Stock Report on Nuvalent
Nuvalent Company Profile
Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.
Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.
Read More
- Five stocks we like better than Nuvalent
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Nuvalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvalent and related companies with MarketBeat.com's FREE daily email newsletter.
